ArticleClinical and translational allergy2025

Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial.

Yan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.